Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANISE-II in primary Sjögren's syndrome
2024-516770-29-00Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing Saphnelo with Placebo (2 arms). Primary endpoint: CRESS response at week 24. Started Nov 2024; status: completed.
02
Drugs
anifrolumab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2024-516770-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516770-29-00.